产品详情
文献和实验
相关推荐
3DMed Clinical Laboratory
Medical Laboratory Qualification
Top scientific achievements
Sample Collection
Sample Preparation
Sample Extraction
Qpcr-Reagent
testing.思路迪（3DMed）2010年成立于上海，是最早在中国开展肿瘤精准医疗检测服务的公司之一，经过长期的耕耘发展，从集团公司分拆之后的思路迪诊断（注册名全称：埃提斯生物技术（上海）有限公司，以下简称“公司”）已经成为中国自动化和智能化精准诊断领域的领*者之一。
目前，公司员工超过1000人，研发人员超过300人，申请/拥有的专利近200项，已经构建了集成设备工程、电气、生命科学技术、材料学和人工智能数据分析为一体的综合性研发平台，具备实现精准诊断领域研发制造全自动化操作以及智能化数据处理的能力。公司还拥有具备行业权威的CAP/CLIA资质的第三方医学检验所，覆盖精准诊断营销网络超过70%的核心三甲医院，服务对象超过800家医院，提供从疾病早期诊断、伴随诊断到疾病动态监测的精准医疗全程管理产品和服务
3D Medicines (3DMed), founded in 2010, is a leader in precision medicine in China dedicated to making early and personalized diagnosis accessible to each patient.
3DMed set the standard of innovation in automated molecular diagnostics and artificial intelligence (AI) to help physicians leverage genetic information to tailor treatment to individual patients.
3DMed clinical laboratory is accredited by College of American Pathologists (CAP) and certified by Clinical Laboratory Improvement Amendments (CLIA) to provide clinical testing in various disease areas. CAP CLIA About 3DMed
In 2018, 3DMed introduced an AI-based cancer genome data interpretation system, the ANDiS Genome Insight.
In late 2019, 3DMed launched a leading fully closed automated NGS library-prep system, the ANDiS 400.
3DMed aspires to be a game changer by offering a diverse pipeline of automated molecular diagnostics.
Soon after the coronavirus 2019 (COVID-2019) outbreak, 3DMed responded rapidly by developing a series of RT-qPCR-based tests (the ANDiS SARS-CoV-2 Detection Kit and the ANDiS SARS-CoV-2 & Influenza A/B Detection Kit) for qualitative detection of SARS-CoV-2 RNA in upper and lower respiratory specimens collected from individuals who meet the CDC criteria for SARS-CoV-2
Medical Laboratory Qualification
Top scientific achievements
Sample Collection
Sample Preparation
Sample Extraction
Qpcr-Reagent
testing.思路迪（3DMed）2010年成立于上海，是最早在中国开展肿瘤精准医疗检测服务的公司之一，经过长期的耕耘发展，从集团公司分拆之后的思路迪诊断（注册名全称：埃提斯生物技术（上海）有限公司，以下简称“公司”）已经成为中国自动化和智能化精准诊断领域的领*者之一。
目前，公司员工超过1000人，研发人员超过300人，申请/拥有的专利近200项，已经构建了集成设备工程、电气、生命科学技术、材料学和人工智能数据分析为一体的综合性研发平台，具备实现精准诊断领域研发制造全自动化操作以及智能化数据处理的能力。公司还拥有具备行业权威的CAP/CLIA资质的第三方医学检验所，覆盖精准诊断营销网络超过70%的核心三甲医院，服务对象超过800家医院，提供从疾病早期诊断、伴随诊断到疾病动态监测的精准医疗全程管理产品和服务
3D Medicines (3DMed), founded in 2010, is a leader in precision medicine in China dedicated to making early and personalized diagnosis accessible to each patient.
3DMed set the standard of innovation in automated molecular diagnostics and artificial intelligence (AI) to help physicians leverage genetic information to tailor treatment to individual patients.
3DMed clinical laboratory is accredited by College of American Pathologists (CAP) and certified by Clinical Laboratory Improvement Amendments (CLIA) to provide clinical testing in various disease areas. CAP CLIA About 3DMed
In 2018, 3DMed introduced an AI-based cancer genome data interpretation system, the ANDiS Genome Insight.
In late 2019, 3DMed launched a leading fully closed automated NGS library-prep system, the ANDiS 400.
3DMed aspires to be a game changer by offering a diverse pipeline of automated molecular diagnostics.
Soon after the coronavirus 2019 (COVID-2019) outbreak, 3DMed responded rapidly by developing a series of RT-qPCR-based tests (the ANDiS SARS-CoV-2 Detection Kit and the ANDiS SARS-CoV-2 & Influenza A/B Detection Kit) for qualitative detection of SARS-CoV-2 RNA in upper and lower respiratory specimens collected from individuals who meet the CDC criteria for SARS-CoV-2
北京美科美生物技术开发有限公司
代理商实名认证
钻石会员
入驻年限：11年
